MannKind stock reaction and recent performance snapshot

MannKind (MNKD) has drawn attention after recent share price swings, with the stock rising about 25% over the past week and around 38% over the past month, despite negative year to date and 1 year returns.

The recent surge, including a 7 day share price return of 25.4% and a 30 day gain of 38.1%, comes after a weaker patch where the 90 day share price return is a 38.6% decline and the 1 year total shareholder return is a 23.3% loss. Momentum has recently turned more positive even as longer term performance remains under pressure.

If MannKind’s latest move has you thinking about where else growth stories could emerge in healthcare, it may be worth scanning 35 healthcare AI stocks

With MannKind trading at US$3.55, a market value of about US$1.1b and an analyst price target of US$7.22, the key question is whether the current discount signals opportunity or if the market already reflects future growth.

Most Popular Narrative: 50.5% Undervalued

The most followed narrative pegs MannKind’s fair value at about $7.17 per share versus the recent $3.55 close, describing a wide gap that hinges on future growth and margins.

Afrezza's continued double-digit prescription growth, international expansion efforts, upcoming pediatric indication launch, and a broadened salesforce footprint are set to accelerate market penetration amid a rising global diabetes burden and an aging population, directly supporting revenue and earnings growth. Multiple late-stage pipeline programs (inhaled clofazimine for NTM and nintedanib DPI for IPF) are progressing toward key regulatory and clinical milestones, benefiting from expedited pathways and growing unmet need in chronic respiratory diseases, with the potential to significantly diversify and expand future revenues.

Curious what kind of revenue curves and margin expansion are built into that view? The narrative leans on aggressive growth, richer profitability and a higher future earnings multiple. The detailed timeline and assumptions behind those targets may surprise you.

Result: Fair Value of $7.17 (UNDERVALUED)

However, this depends on Afrezza expanding beyond its niche and on Tyvaso DPI royalties remaining resilient if United Therapeutics proceeds with a soft mist inhaler.

Next Steps

With sentiment clearly split between risks and rewards, this is the moment to look through the details yourself and decide where you stand. You can start with 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If MannKind has sharpened your focus, do not stop here. The right screener can surface stocks you might otherwise miss and reshape your watchlist fast.

• Target potential mispricing by scanning 51 high quality undervalued stocks that combine solid fundamentals with room for a rerating.
• Strengthen your defense by reviewing 72 resilient stocks with low risk scores that score well on stability and downside protection.
• Get early to lesser known opportunities using the screener containing 23 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.